Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further [...]
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further [...]
Seeking an edge over Amgen, Mirati advances lower KRAS dose [...]
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse [...]
Gyroscope spins the wheel again as it taps Sanofi for [...]
GSK pulls off clean sweep of endpoint hits in anemia [...]
Blackstone bets on Autolus’ CD19 CAR-T in $250M deal, clearing [...]
Treating drug-resistant prostate cancer by exploiting tumor-suppressing RNA arlene.weintraub Fri, [...]
UPDATE: Pfizer’s oral COVID-19 antiviral cuts hospitalization, death by 85%, [...]
HitGen taps Cambridge Molecular for ‘deep learning’ drug discovery collab [...]
Moderna scraps lead mRNA chikungunya candidate after phase 1, slowing [...]